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Objective: Leptospirosis pulmonary hemorrhage syndrome (LPHS) is a severe form of 
leptospirosis, with a case fatality rate exceeding 50%. Recently, LPHS has become the principal 
cause of mortality in leptospirosis patients in Salvador, Brazil. This study aims to describe the 
epidemiology of LPHS since 2003, characterize its clinical presentation, and identify risk factors 
that distinguish it from non-hemorrhagic pulmonary (NHPL) and non-pulmonary (NPL) forms. 
Methods: Patients admitted between January 1, 2003 and December 31, 2012 in the active 
hospital-based surveillance who met the clinical case definition were included in the study. A 
standardized questionnaire was used to collect data from patient charts and in-person interviews. 
Unadjusted logistic regression models identified individual-level risk factors. Maps showing 
spatial distribution and clustering of leptospirosis cases were created to identify high risk areas. 
Results: We identified 1,316 patients meeting our case definition, which included 113 LPHS, 
184 NHPL, and 1019 NPL cases. Males were at greater risk for LPHS in all age groups. The 
LPHS-associated mortality was 65.5% (95% CI: 56.33-73.63), compared to 30.4% and 6.2% for 
NHPL and NPL cases, respectively. A lower microagglutination test (MAT) titer for LPHS 
compared to NPL cases in the acute phase suggests the absence of an early robust immune 
response. A high-risk LPHS cluster (p= 0.01) was identified and rat sightings was associated 
with NHPL patients (OR: 2.77, 95% CI: 1.23-6.23). Limited unique clinical correlates observed 
in patients with pulmonary manifestations compared to non-pulmonary forms of leptospirosis. 
Conclusion: We describe the clinical features and epidemiology of LPHS in Salvador, Brazil, 
since its emergence in 2003. Few clinical correlates were identified between LPHS and NHPL 
patients, suggesting that leptospirosis is a disease on a clinical spectrum. Multidimensional 
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Leptospirosis pulmonary hemorrhage syndrome (LPHS) is an emerging, fatal form of 
leptospirosis worldwide [1–8]. LPHS presents differently than the classic form known as Weil’s 
disease, which is characterized by jaundice, acute renal failure, and bleeding. An outbreak of 
LPHS in Nicaragua in 1995 following a period of heavy rainfall raised awareness for this form of 
leptospirosis as LPHS patients did not display significant renal dysfunction or jaundice, 
suggesting that LPHS is a de novo form of leptospirosis [3,9]. However, differences in clinical 
presentation may vary according to geographic locale [10].   
 
Around the world, the incidence of pulmonary involvement ranges from 20 to 70% of cases, with 
a spectrum of clinical manifestations, including mild or asymptomatic forms to pulmonary 
hemorrhagic forms [6, 11]. However, the burden of leptospirosis may be grossly underestimated 
even in endemic areas due to poor diagnostic tools and limited epidemiological studies on the 
clinical characteristics specific to patients with LPHS. As an example, in Iquitos, Peru,  an area 
endemic to other febrile illnesses, including dengue and malaria, Vinetz et al describe the 
challenges of identifying leptospirosis-associated pulmonary manifestations due its non-specific 
febrile presentation [12]. Likewise, in Salvador, Brazil, the co-endemicity of leptospirosis and 
dengue hampers surveillance efforts. The delay in treatment may explain, in part, the reason 
behind poor clinical outcomes for patients with severe forms of leptospirosis [13].  The severity 
of LPHS in Salvador is documented by case fatality rates exceeding 50%, which is among the 
highest in endemic settings [1].   
 
Prior to May 1, 2003, LPHS was not a recognized form of leptospirosis in Salvador, Brazil [1]. 
Under-recognition of leptospirosis is a limitation due to early non-specific influenza-like 
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presentation and the presence of other hemorrhagic fevers, but this was probably not the case in 
Salvador since other cities in Brazil had previously identified cases of LPHS [1, 14]. 
Leptospirosis is a reportable disease in Brazil, but estimates of the burden of leptospirosis are 
poor due to insensitive diagnostic tools, non-differential presentation from other hemorrhagic 
fevers during acute infection, and limited resources.  
 
This study aims to provide an assessment of the burden of LPHS in Salvador, Brazil since its 
emergence in 2003. An understanding of the epidemiological burden, risk factors for the 
acquisition of disease, and clinical characteristics of LPHS is of critical importance as the 
world’s urban population is projected to grow by 2 billion before 2030[15]. A study by Gouveia 
et al on LPHS patients in Salvador, Brazil, from 2003-2005 identified important characteristics 
that this study aims to reexamine using additional patient data from 2003-2012. Increased 
awareness of risk factors for LPHS and an epidemiological assessment of leptospirosis across 
Salvador are necessary in order to reduce the number of preventable leptospirosis-associated 












Surveillance site and data collection 
All cases of leptospirosis were identified in Salvador, a coastal city with three million inhabitants 
in northeastern Brazil. Between January 1, 2003 and December 31, 2012, all patients with a 
clinical suspicion of leptospirosis admitted to Hospital Couto Maia (HCM), the state-run 
infectious disease referral hospital, were included in the study. All suspected cases must be 
communicated to the state health secretary and patients in the metropolitan area are referred to 
HCM.  
 
Informed consent was obtained from patients or caretakers following guidelines instituted by the 
institutional review boards of the Brazilian Ministry of Health (the Oswaldo Cruz Foundation, 
FIOCRUZ) and Yale University. A standardized questionnaire was used to collect demographic 
data, risk factors, including household and occupational exposures through in-person interviews 
with patients or caretakers for all patients meeting the clinical case definition. Medical chart 
reviews were performed to collect clinical data, including laboratory or clinical symptoms on 
admission in addition to data during hospitalization. 
 
Clinical case definition 
Patients were enrolled if they met the clinical definition of severe leptospirosis upon admission. 
The minimum requirement for inclusion was a measured or self-reported fever (>38˚C) and 
being at least five years of age. In addition, patients must meet at least one of the syndromic 
criteria on admission to be enrolled. Acute renal insufficiency (oliguria or serum creatinine >1.5 
mg/dL), jaundiced appearance noted during physical examination (or self-report), or liver 
enzyme alteration (total bilirubin >3.0 mg/dL or 75 U/L <TGO <3000 U/L or 75 U/L TGP 
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<3000 U/L). With respect to bleeding, patients must present with spontaneous hemorrhaging not 
explained by trauma. Examples of eligible forms of hemorrhage include: pulmonary hemorrhage 
or hemoptysis, petechiae, or gastrointestinal hemorrhage. Additional clinical presentations for 
inclusion include:  bilateral conjunctival suffusion, enteric fever (malaise, vomiting, diarrhea, 
constipation, abdominal pain, and headache), undifferentiated febrile syndrome, meningitis or 
encephalitis with cerebrospinal fluid results consistent with an aseptic inflammatory process (10-
2,000 cells/μL; glucose >40 mg/dL; proteins <150 mg/dL), or high clinical suspicion of 
leptospirosis upon examination. 
 
Patients were excluded from the study if they presented with clinical or laboratory evidence of a 
diagnosis other than leptospirosis, refused to provide informed consent, readmitted for follow-up 
care of the same syndrome for the same episode, or experienced more than fifteen days of fever.  
 
Laboratory Confirmation 
The microagglutination test (MAT) was performed to confirm the diagnosis of leptospirosis 
serologically for all cases when possible. Laboratory-confirmed diagnosis of leptospirosis was 
defined as a four-fold rise in MAT reciprocal titer between paired serum samples, a reciprocal 
titer greater than 800 in one or more serum samples, or seroconversion was defined as a change 
in paired serum samples from a negative microagglutination titer to a reciprocal titer greater than 
200. We also considered a positive result on the immunoglobulin M (IgM) ELISA (Bio-
Manguinhos, Rio de Janeiro, Brazil) from any sample, isolation of leptospires in hemoculture, or 
detection of leptospires in real-time polymerase chain reaction (PCR) as laboratory-confirmed. 
Laboratory results interpreted as “probable,” including a single reciprocal MAT titer of 200 or 
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400 without serconversion; or a borderline positive IgM ELISA without seroconversion, were 
not considered confirmed for this analysis. 
 
Outcome Case Definition: LPHS, NHPL, and NPL Case Definitions 
Three primary outcomes include death, leptospirosis pulmonary hemorrhage syndrome (LPHS), 
and non-hemorrhagic pulmonary leptospirosis (NHPL).  Death was defined as documentation in 
the patient’s chart. LPHS was defined as having clinical suspicion of leptospirosis and massive 
pulmonary hemorrhage (blood coughed from lungs greater than 250 c.c. or aspiration of fresh 
blood after endotracheal intubation, which did not clear with suctioning). NHPL was defined as 
clinical suspicion of leptospirosis and respiratory distress without massive pulmonary 
hemorrhage. Respiratory distress was defined as having a maximum respiratory rate of at least 
35 inhalations per minute or mechanical ventilation.  Finally, non-pulmonary leptospirosis (NPL) 
was defined as having a clinical suspicion of leptospirosis without pulmonary manifestations.  
 
We used the following clinical characteristic definitions for our study: hypotension was defined 
as a systolic blood pressure less than 90 mmHg; thrombocytopenia as having a platelet count less 
than 50,000 cells per cubic mm; oliguria as a 24 h urine volume of less than 400 mL at any time 
during hospitalization; and dialysis as peritoneal or hemodialysis.  
 
Cases included in the study 
Interviews were conducted on 1,316, patients who met the case definition for clinical suspicion 
of leptospirosis. Of the, 1,316 case patients, 1,049 (79.9%) were laboratory-confirmed, 17 (1.3%) 
were probable cases, and 250 (19.0) were unconfirmed (S3). Serologic confirmation could not be 
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completed for 21 (8.4%) of the 250 unconfirmed cases because paired serum samples were not 
obtained. Confirmed, probable and unconfirmed cases differed in demographic and clinical 
characteristics; however, due to high case fatality ratio among severe cases of leptospirosis, we 
included all patients who met the clinical case definition for the analysis of individual level 
exposure analysis and clinical characteristics analyses to prevent selection bias of patients with 
less severe disease (Tables 3, 4). 
 
Environmental Data 
Place of residence for patients enrolled in the hospital-based surveillance at HCM were geo-
located during community-home visits following discharge from the hospital. A standardized 
questionnaire was used to assess individual level risk factors at the household level, including 
ownership of domesticated pets (dogs, cats, chickens), rat sightings, exposure to contaminated 
sources at home or at work, contact with floodwaters during the rainy season, and knowledge 
about incident cases of leptospirosis in the vicinity. All data collected were stored electronically 




Population estimates for the city of Salvador were obtained from the 2010 population census for 
Salvador-Bahia, Brazil, collected by the Instituto Brasileiro de Geografia e Estatística (IBGE) 
(http://www.ibge.gov.br/english/estatistica/populacao/censo2010/). Census data were used to 
calculate mean annual incidence rates of cases of leptospirosis (LPHS, non-LPHS, all cases) per 




The odds ratios and 95% confidence interval (CI) for acquiring LPHS in men compared to 
women, by age group with the 0-14 age group as the reference category, and the odds of death 
for LPHS patients compared to non-LPHS patients were calculated using a Chi-square test. CIs 
for case fatality ratios were calculated using the Wald method in GraphPad 
(http://graphpad.com/quickcalcs/ConfInterval1.cfm). Confidence intervals that did not include 
1.0 were considered statistically significant.  
 
A generalized additive model (GAM) analysis was performed to display the non-linear trend 
between death and age; the acquisition of the type of leptospirosis (LPHS, NHPL, or NPL) and 
age. Models displayed show the fitted probability of death by LPHS, NHPL, NPL, or all deaths 
caused by leptospirosis by age. Age was modeled as a continuous variable.  
 
Spatial cluster detection 
SaTScan software [16] was used to identify spatial clustering of LPHS cases and non-LPHS 
(NHPL and NPL) cases. Kulldorff’s scan statistic was calculated by using a moving circular 
window to test whether cases were distributed randomly over space, and to identify high LPHS 
clusters. The statistic was set to include a maximum of 50% of the data. A Bernoulli model was 
used to model the dichotomous outcome variable (LPHS or non-LPHS). The two analyses 
performed in SaTScan were: purely spatial across the ten-year period, from 2003-2012 and a 
retrospective spatial-temporal analysis, with time represented in one-year increments to account 
for seasonal variation. Patient homes were georeferenced to the Universal Transverse Mercator 





Daily rainfall data from January 1, 2003 to December 31, 2012 were obtained from the Instituto 
Nactional de Meteorologia (INMET) for Salvador-Bahia, Brazil 
(http://www.inmet.gov.br/portal/). Rainfall was collected each day in millimeters (mm) and 
summed over the entire month in order to examine the seasonal trend of rainfall (rainy season 
versus dry season). Cases of leptospirosis were separated by the severity of disease (LPHS, 
NHPL, and NPL) in order to determine if cases of leptospirosis by severity are associated with 
rainfall. LPHS cases were plotted beneath the x-axis in order to more closely examine the 
association between rainfall and the number of LPHS cases compared to non-LPHS cases.  
 
Risk factor and clinical characteristic analyses 
We used the Chi-square and Fisher’s Exact tests to compare categorical data and the Wilcoxon 
rank sum test to compare non-parametrically distributed continuous data for two pairwise 
analyses: LPHS/NPL and NHPL/NPL. A P-value of <0.05 using a two-sided test was considered 
statistically significant. An unadjusted analysis using unconditional logistic-regression models 
was used to calculate crude odds ratios and their 95% confidence intervals for individual level 
risk factors for acquiring leptospirosis. In this study, multivariate analyses were not performed 
because the primary goal is to provide a descriptive examination of clinical characteristics 
observed on admission.  
 
Study data were collected and managed using REDCap (v.5.6.4) electronic data capture tools 
hosted at the Brazilian Ministry of Health (Oswaldo Cruz Foundation, FIOCRUZ).  
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SAS for Windows (version 9.3) software was used for the statistical analysis of the data, R 
version 3.0.3 statistical package (R Foundation for Statistical Computing) was used to plot the 
GAM analysis, GraphPad PRISM (version 6.00) was used to produce figures and associated 95% 
confidence intervals for the demographic data, and maps were produced in ArcGIS (ArcGIS 10.2 






















Descriptive epidemiological findings 
Person 
Between January 1, 2003 and December 31, 2012, 1,316 hospitalized patients met the 
surveillance case definition for leptospirosis. Among the cases, 113 (8.6%) had pulmonary 
hemorrhagic leptospirosis (LPHS), 184 (14.0%) had non-hemorrhagic pulmonary leptospirosis 
(NHPL), and 1,019 (77.4%) had non-pulmonary leptospirosis (NPL) manifestations. The annual 
incidence rate of leptospirosis in Salvador, Brazil was 3.73 cases per 100,000 persons, compared 
to 0.31 and 3.43 cases per 100,000 persons for LPHS and non-LPHS cases (S1).  
 
Young adult males between the ages 15-29 (31.5%) and 30-44 (27.1%) represented the majority 
of patients enrolled (Figure 1A). The risk of acquiring LPHS was greatest among individuals 
between the ages 15-29 (OR: 1.06, 95% CI: 0.40-2.80) and 60 years of age or older (OR: 1.93, 
95% CI: 0.65-5.67), but were not statistically significant (Table 1). Overall, the odds of males 
acquiring LPHS was greater than females except for males between 15-29 years of age, where a 
58% decrease (OR: 0.42, 95% CI: 0.18-0.98) in acquiring LPHS among men compared to 
women was observed (Table 1).  
 
The overall case fatality rate was 14.7% (193 deaths); of which 65.6% (74) were caused by 
LPHS followed by 30.4% (56) and 6.2% (63) for NHPL and NPL forms, respectively (Figure 
1B). Patients between the ages 45-59 had the highest case fatality rate (84.0%, 95% CI: 64.7-
94.2) (Figure 1B, C, S2). Across all age groups, the odds of LPHS associated death was 17.28 
(95% CI: 11.23-26.61) compared to non-LPHS associated death (Table 2).  GAM analysis for 
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the acquisition of leptospirosis by type (i.e. LPHS, NHPL, NPL) and leptospirosis-associated 
death by age did not display a linear dose-response trend with increasing age (SF1). The fitted 
probability for death in LPHS and NHPL patients across age increased in a parabolic fashion, 
with the highest probability of death in individuals between 40 to 60 years of age (Figure 2A, B). 
Among individuals with non-pulmonary manifestations of leptospirosis, death increased 
exponentially (Figure 2C). Finally, overall leptospirosis-associated death increased in a semi-
linear fashion with age, with a slight elevation in the probability of death for individuals between 
35 to 50 years of age (Figure 2D). 
 
Place 
During the study period, a total of 999 leptospirosis cases residing in the City of Salvador were 
enrolled. Of these, 897 (89.8%) patients had associated GIS coordinates, which were obtained 
during follow-up home visits. Among the cases distributed in Salvador, 75 (8.4%) LPHS, 127 
(14.2%) NHPL, and 695 (77.5%) NPL cases were documented (Figure 3A). A significant 
(p=0.010) high-risk cluster for LPHS cases in relation to non-LPHS cases compared to other 
regions in Salvador was identified in Pirajá by spatial analysis (Figure 3B). Pirajá is a one of the 
most densely populated districts in Salvador, with a population of 337,667 residents older than 
10 years of age, according to the 2010 census[17]. Similarly, a spatial-temporal analysis of high-
risk areas for LPHS cases identified a significant (p=0.014) geographic cluster in Pirajá. A higher 
proportion of LPHS cases compared to other locations in the City of Salvador existed from 






In Salvador, Brazil, the quantity of rainfall was associated with the overall number of cases of 
leptospirosis, but rainfall did not correspond with the proportion of LPHS cases. The majority of 
leptospirosis cases were identified during the rainy months, which ranged from April to August 
(Figure 4). As an example, during the heaviest year of rainfall (2005), 15.1% of all cases of 
leptospirosis in our study were identified. Out of 199 (15.1%) cases of leptospirosis reported in 
2005, 15.1% (30 cases) were LPHS cases. However, the greatest proportion of LPHS cases was 
identified in 2008, a year with approximately 40% less rain than in 2005. LPHS represented 
17.3% out of 104 leptospirosis cases, which accounted for 7.9% of the overall number of 
leptospirosis cases enrolled in 2008. Furthermore, in the driest year (2012) LPHS cases 
represented 8.57% of cases in 2012, which is comparable to the proportion of LPHS cases 
(8.64%) in 2010 (the fifth wettest year in the study and the year with the second largest number 
of leptospirosis cases, 162).  
 
The number of leptospirosis cases is approximately equally divided between the two five-year 
segments in the study period. From 2003 to 2007, 55.6% (732) of all cases of leptospirosis cases 
were identified. Among the 732 cases identified during this time period, 61patients had LPHS, 
which represents 54% of all LPHS cases from 2003-2012. The number of leptospirosis cases and 
LPHS cases were marginally less in the second half of the study period (2008-2012).  
 
Individual-level exposures and clinical presentation 
Individual level exposures, including occupation, domiciliary, and environmental factors did not 
differ significantly between LPHS and NPL patients. A high proportion of LPHS (83.7%), 
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NHPL (81.6%), and NPL (81.4%) patients lived near refuse and consequently reported between 
two to six rats per day near their homes (Table 3). No significant differences were observed for 
patients with pulmonary manifestations compared to NPL patients in terms of exposure to 
contaminated sources potentially harboring Leptospira near domiciles including contact with 
contaminated waters from open sewers or street, house, or backyard flooding during the rainy 
season. Similarly, no significant differences were identified with respect to contact with 
contaminated sources at work including mud, trash, flood water, and sewer water. 
Approximately 20% of patients in each group reported use of protective equipment, such as 
boots or gloves, when in contact with mud, trash, flood water, or sewer water at work. No 
significant difference associated with limited use of protective equipment and outcome was 
detected.  
 
However, we identified two risk exposures related to zoonotic reservoirs that were positively 
associated with development of NHPL. NHPL patients had an elevated unadjusted odds of 
observing rats near their homes (OR: 2.93, 95% CI: 1.48-5.81) compared to NPL patients. 
Additionally, the unadjusted odds of owning a domesticated dog among NHPL patients was 67% 
higher (95% CI: 1.10-2.55) than NPL patients.  
 
Although individual level exposures did not differ between LPHS and NPL patients, clinical 
characteristics and laboratory tests based on serology indicate host level differences in the 
clinical presentation of disease. Among laboratory confirmed cases of leptospirosis, serovar 
Copenhageni was the primary infecting agent (>90%) for all cases of leptospirosis in Salvador.  
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LPHS patients had a lower acute phase reciprocal MAT titer (0.0, IQR: 0.0-150.0) compared to 
NHPL (0.0, IQR: 0.0-400.0) and NPL patients (200.0, IQR: 0.0-1600.0). On the other hand, 
convalescent titers for LPHS were greater than NPL patients 6400.0 (IQR: 800.0-6400.0) 3200.0 
(IQR: 400.0-6400.0), respectively.  
 
LPHS patients admitted to the hospital presented with more severe clinical characteristics on 
admission and during hospitalization. Among the 95 LPHS patients who responded, 39 (41.1%) 
had hemoptysis within the first 24 hours of hospital admission. During hospitalization, 107 
(99.1%) out of 108 LPHS patients reported having hemoptysis (S4). The proportion of intensive 
care unit admission was 5.5 times higher for LPHS patients compared to NPL patients, 86.1% 
and 15.7%, respectively (Table 4). Aggressive therapeutic interventions during hospitalization 
including dialysis and blood transfusion were performed on a greater proportion of LPHS 
patients compared to NPL patients. More specifically, dialysis was performed on 55.1% of LPHS 
patients compared to 18.5% of NPL patients (p <0.0001); 56.1% of LPHS patients received 
blood transfusion compared to 9.1% of NPL patients (Table 4).  
 
On admission, 66.3% of LPHS patients reported shortness of breath and 16.0% were hypotensive 
(Table 4). Additionally, 51 (58.6%) of LPHS patients presented with oliguria on admission 
compared to 263 (30.9%) for NPL patients (p <0.0001). During the course of hospitalization the 
number of LPHS and NPL patients with oliguria increased to 83 (83.8%) and 474 (53.5%), 




Laboratory results detected elevated liver enzyme function of aspartate aminotransferase (TGO) 
in LPHS patients (126.0 U/L, IQR: 60.0-277.0) compared to NPL patients (86.0 U/L, IQR: 52.0-
148.0) (Table 3). The percentage of hematocrit in whole blood was significantly lower 
(p<0.0001) in LPHS patients (30.0, IQR: 26.0-34.0) compared to NPL (35.0, IQR: 31.1-39.1) 
patients.  LPHS patients were more thrombocytopenic (<50,000 platelet cells/mm
3
) than NPL 





















Leptospirosis is an important emerging infectious disease as a result of rapid urbanization in 
Brazil. In Salvador, Brazil, LPHS was not identified prior to May 1, 2003 [1], but cases of 
pulmonary manifestation had been reported since the mid 1980’s in other large urban areas in 
Brazil (Rio de Janeiro and Sao Paulo) [10, 18,19]. The high case fatality rate observed in LPHS 
patients calls for heightened awareness and the need to critically evaluate epidemiologic factors 
associated with this fatal form of leptospirosis.  In this study we have continued the work 
initiated by Gouveia et al by performing a descriptive analysis over ten years (2003-2012) since 
the first documented case of LPHS in Salvador, Brazil.   
 
Our study attempts to characterize the epidemiology of severe forms of leptospirosis despite 
diagnostic challenges and high case fatality rates, which hinder surveillance capacity in well-
established sites. Laboratory confirmation was obtained for 70% of LPHS cases enrolled, which 
indicates that LPHS was caused by Leptospira infection and not by other endemic hemorrhagic 
diseases.  Although cases of LPHS represent fewer than 10% of all leptospirosis cases in our 
hospital-based surveillance, it is the leading cause of mortality among hospitalized patients with 
leptospirosis in Salvador. Despite the attenuation in the overall case fatality rate due to LPHS in 
Salvador since Gouveia et al’s study (74% to 66%), it is important to close the knowledge gap 
regarding key risk factors associated with LPHS, whether they are individual-level exposures or 
clinical characteristics.  
 
Specific individual-level exposures unique to the acquisition of LPHS compared to non-
pulmonary forms of leptospirosis were not identified in our study and observed by Gouveia et al 
[1]. Other studies performed in large urban communities in Salvador also did not find an 
19 
 
association between environmental factors and Leptospira infection [20].  However, in our study, 
sighting of rats near the home and the ownership of a domestic dog were significant unadjusted 
risk factors for the development of NHPL. This suggests that perhaps the development of LPHS 
does not correspond to an increase in inoculum dose from contact with known reservoirs. Early 
detection of LPHS cases with respect to individual-level exposures will be difficult since LPHS 
cases did not have significantly different exposures compared to NPL patients. Therefore, a high 
clinical index of suspicion for patients with symptoms of respiratory distress is necessary to 
prevent the progression to LPHS.  
 
Results from our clinical and individual risk factor questionnaire suggest that LPHS does not 
have a discrete phenotype. Instead, LPHS is a severe form of leptospirosis, which runs on a 
clinical spectrum and individuals may progress from mild or asymptomatic forms to respiratory 
distress, and finally massive pulmonary hemorrhagic forms. A greater proportion of LPHS 
patients present with severe clinical characteristics on admission and progress during 
hospitalization. Pulmonary hemorrhage was identified in 41.1% of LPHS patients on admission, 
but increased to 99.1% among LPHS patients during hospitalization (S4). Furthermore, MAT 
titers of LPHS patients are lower on admission compared to NPL patients, followed by increased 
titers during hospitalization.   
 
Specific clinical exposures unique to LPHS patients were not identified compared to NHPL 
patients. This suggests that host specific responses play an important role in the development of 
severe disease. In Salvador, L. interrogans serovar Copenhageni is the causative agent for 90% 
of cases. A study on rats in Salvador, Brazil positively identified 68.1% of rats (Rattus 
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norvegicus) sampled near the homes of hospitalized patients with severe leptospirosis as carriers 
of serovar Copenhageni [21]. Genomic studies have not identified differences in isolates from 
LPHS patients compared to non-LPHS patients suggesting non-differential association between 
pathogenicity and clinical outcome (unpublished).  Additionally, intensity of exposure to rainfall 
does not result in a greater number of LPHS cases. Although our study supports the established 
idea that leptospirosis cases are associated with rainfall [3, 9, 22, 23, 24, 25,26], the proportion 
of LPHS cases does not follow always follow the pattern of rainfall. These observations indicate 
that host response, such as the role of the immune system, may explain why certain individuals 
develop LPHS while others do not. 
 
A spatial and temporal analysis identified Pirajá, a densely populated area, as a high risk area for 
LPHS, particularly from 2004-2008. Although it is difficult to explain why Pirajá is a high risk 
LPHS area, it is of great public health importance to note that high risk clusters have not been 
observed since 2008. For public health practitioners, this finding may shed light on future 
hotspots in Salvador that have similar terrain, exposures, and spatial distribution of residents. 
Predictive risk mapping for leptospirosis is a novel concept that has only been performed on data 
from the American Samoa and has the potential to assist with control programs targeting high 
risk areas[27]. Of note, an ongoing prospective community-based cohort study for leptospirosis, 
dengue, and non-communicable illnesses is based in an urban slum community situated in Pirajá 
[13, 20,21, 24, 28]. Reporting bias is not a major concern since our hospital-based surveillance 
covers the entire city of Salvador. Efforts to reduce the burden of leptospirosis in urban slum 
communities have led to closure of open sewers, attention to the need for improved sanitation 
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measures, and awareness of leptospirosis in the community. This may explain the decreasing 
burden of leptospirosis in the last half of our ten-year study.  
 
Gouveia et al, identified that women were twice as likely as men to acquire LPHS[1]. However, 
in this follow-up study, the gender effect has been attenuated. Men are at greatest risk for 
acquiring leptospirosis and LPHS across all age groups, but men between the ages 15-29 have a 
58% reduction in the odds of acquiring LPHS (OR: 0.42, 95% CI: 0.18-0.98). Host 
susceptibility, participation in risk activities, and changes in the social infrastructure may explain 
the increased risk for LPHS for women in this age group.  
 
The burden of leptospirosis primarily exists among populations residing in resource-poor 
settings. It is a preventable infectious disease that requires improvements in basic sanitation 
measures, changes in infrastructure, enhanced awareness of risk factors for disease, and 
resources for health care [15,29]. Although LPHS constitutes less than 10% of the cases of 
leptospirosis in Salvador, Brazil, the mortality is exceptionally high. High mortality may result 
from delayed treatment due to non-specific presentation during acute infection [13, 30]. This 
study demonstrates that leptospirosis is a disease that manifests on a clinical spectrum, therefore 
early identification of cases and control programs targeting rat control in densely populated areas 
may reduce the burden. Studies focusing on host factors and exposure to contaminated sources 
are needed for the development of effective control programs to reduce the number of 






In this study, information was analyzed from patients who met the surveillance case definition of 
leptospirosis. These included unconfirmed cases (19.0% of 1,316) and probable cases (1.3% of 
1,316) primarily due to incomplete diagnostic testing because of the lack of paired serum 
samples. Cases without lab confirmation were older, more likely to be female, and had higher 
mortality (S5). As a result, exclusion of the unconfirmed patients might bias the results by failing 
to recognize a subgroup of severely ill patients.  A potential limitation to this inclusion criterion 
is the potential for misclassification of patients, which calls for improved diagnostic tests for 
early detection of leptospirosis. Other limitations of this study are the lack of data for individual-
level exposures to contaminated sources, environmental reservoirs, and sanitary conditions. 
Finally, due to the cross-sectional nature of the data, it is difficult to fully characterize and 
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Figure 1: Demographics: Clinically suspected cases of leptospirosis, according to age and 
sex, in Salvador, Brazil, from 2003-2012.  A. Demographics of suspected cases of 
leptospirosis, according to age and sex. Black bars, male cases; gray bars, female cases. B. 
Distribution of 193 leptospirosis-associated deaths among all suspected cases of leptospirosis 
according to age. Deaths among case-patients with LPHS represented by black bars (    ), death 
among case-patients with NHPL represented by hatched bars ( ), and death among case-
patients with NPL represented by white bars (    ).  C. Solid circles, LPHS case fatality rate 
(CFR) (    ), solid square with dashed line, CFR for NHPL cases (     ), and solid triangle, CFR 
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 Figure 2: Generalized additive models (GAM) of the association between the probability of 
leptospirosis-associated death for patients with A. LPHS, B. NHPL, C. NPL, and D. all forms of 
leptospirosis by the continuous variable of age.  The coefficient, fitted probability of death, in the 

















Figure 3: Risk mapping: spatial and temporal distribution of leptospirosis cases in the City 
of Salvador, Brazil, from 2003-2012. Spatial distribution of 897 suspected cases of 
leptospirosis in Salvador, Brazil with geocoding from 2003-2012 (N=999). A. The distribution of 
suspected cases of leptospirosis with GIS coordinates residing in the City of Salvador. Pink dots, 
LPHS cases; blue dots, NHPL cases; green dots, NPL cases. The population (persons older than 
10 years of age) by census district obtained from the 2010 Census is shown*. B. A high risk area 
for LPHS compared to non-LPHS. Cluster included 26 LPHS cases out of 121 total leptospirosis 
cases (RR 3.40, p=0.010). C. A high risk area for LPHS compared to non-LPHS using spatial-
temporal analysis. Cluster included 7 LPHS cases out of 9 total cases of leptospirosis (RR 10.16, 
p= 0.014).  Cluster significance calculated using Kulldorf’s spatial scan statistic [16]. RR= 
relative risk. 
*2010 Population Census of Salvador-Bahia, Brazil from the Instituto Brasileiro de Geografia e 

































Figure 4: Seasonality: leptospirosis cases and monthly rainfall from 2003-2012. Monthly 
number of clinically suspected cases of leptospirosis (N=1,316) in relation to the monthly 
pluviometric precipitation (mm) in Salvador, Brazil, from January 1, 2003 to December 31, 
2012. The month and year of hospitalization is shown for each case of LPHS, NHPL, and NPL. 


















Table 1:  Risk of acquiring LPHS among 1,316 suspected cases of leptospirosis, according to age and gender. 
 
 


























OR (95% CI)** 
      Age Group 
          All ages 113 1203 1.00 (NA) 92 1024 8.24 21 179 10.50 0.77 (0.46-1.26) 
                0-14 5 53 Ref 4 45 0.36 1 8 0.50 0.71 (0.07-7.21) 
               15-29 42 419 1.06 (0.40-2.80) 34 381 3.05 8 38 4.00 0.42 (0.18-0.98) 
               30-44 27 384 0.75 (0.28-2.02) 25 332 2.24 2 52 1.00 1.96 (0.45-8.51) 
               45-59 25 270 0.98 (0.36-2.68) 16 214 1.43 9 56 4.50 0.47 (0.20-1.11) 
                 60+ 14 77 1.93 (0.65-5.67) 13 52 1.16 1 25 0.50 6.25 (0.77-50.49) 
No., number; OR, odds ratio; CI, confidence interval. Bold values indicate statistical significance. The percentage of LPHS cases 
among all leptospirosis cases in row. 
*OR shown describe the odds of acquiring LPHS in each age group with respect to the 0-14 age group. 










































95% CI OR (95% CI)   
          
All ages 193 1316 14.67 12.85-16.68 74 113 65.49 56.33-73.63 119 1203 9.89 8.33-11.71 17.28 (11.23-26.61) 
             
0-14 4 58 6.90 2.24-16.91 3 5 60.00 22.91-88.40 1 53 1.89 0.00-10.88 78.00 (5.41-1123.71) 
             
15-29 37 461 8.03 5.85-10.89 20 42 47.62 33.36-62.28 17 419 4.06 2.50-6.45 21.50 (9.89-46.71) 
             
30-44 60 411 14.60 11.50-18.36 21 27 77.78 58.90-89.74 39 384 10.16 7.49-13.61 30.96 (11.79-81.33) 
             
45-59 69 295 23.39 18.91-28.56 21 25 84.00 64.73-94.21 48 270 17.78 13.66-22.80 24.28 (7.97-73.96) 
             
60+ 23 91 25.27 17.42-35.13 9 14 64.29 38.60-83.82 14 77 18.18 11.02-28.36 8.10 (2.35-27.91) 
No., number; OR, odds ratio; CI, confidence interval; CFR, case fatality ratio. The OR (95% CI) shown describes the odds of death 










Table 3: Selected unadjusted individual-level risk factors for the acquisition of leptospirosis among 1,316 suspected cases of 
leptospirosis enrolled in the active hospital-based surveillance 
 
LPHS (n=113)   
 








 No. (%) or % 
of group or 
Median (IQR) 





 No. (%) or % 
of group or 
Median (IQR) 
OR (95% CI)   
No. 
Responses 
 No. (%) or % of 
group or Median 
(IQR) 
Demographics and Epidemiological Data 
   
 
      
Age (years) 113 38.0 (23.0-49.0) 1.01 (1.00-1.02) 
 
184 39.0 (26.0-48.0) 
1.01 (1.00-
1.02)  
1019 34.0 (23.0-46.0) 
Sex 
   
 
      
    Male 113 89 (78.8) 0.63 (0.39-1.01) 
 
184 152 (82.6) 0.80 (0.53-1.22) 
 
1019 872 (85.6) 
Ethnicity 
   
 
      
    Black 113 19 (16.8) 0.53 (0.32-0.89) 
 
184 52 (28.3) 1.04 (0.73-1.47) 
 
1019 281 (27.6) 
Individual level risk factors 
   
 
      
Smoke 41 20 (48.8) 0.88 (0.47-1.67) 
 
105 54 (51.4) 0.98 (0.65-1.49) 
 
526 273 (51.9) 
Diabetes 41 2 (4.9) 1.41 (0.32-6.30) 
 
102 9 (8.8) 2.66 (1.16-6.11) 
 
513 18 (3.5) 
Asthma 42 1 (2.4) 0.95 (0.12-7.47) 
 
104 3 (2.9) 1.16 (0.33-4.15) 
 
521 13 (2.5) 
      Type of Job 
                      Formal 8 26.7% 1.16 (0.50-2.68) 
 
18 24.7% 1.29 (0.72-2.29) 
 
114 29.6% 
                Informal 22 73.3% 0.86 (0.37-2.00) 
 
55 75.3% 0.78 (0.44-1.38) 
 
271 70.4% 
       Occupation 
                            Sewer worker 30 3 (10.0) 0.93 (0.27-3.20) 
 
73 11 (15.1) 1.48 (0.72-3.04) 
 
384 41 (10.7) 
                  Mechanic 30 0 (0.0) 1.00 (NA) 
 
73 4 (5.5) 0.64 (0.22-1.87) 
 
385 32 (8.3) 
                  Refuse disposal worker 30 0 (0.0) 1.00 (NA) 
 
73 1 (1.4) 0.25 (0.03-1.91) 
 
384 20 (5.2) 
                  Construction worker 30 14 (46.7) 1.97 (0.93-4.17) 
 
74 28 (37.8) 1.37 (0.82-2.30) 
 
384 118 (30.7) 
Exposure to contaminated sources* 
                             Contact with mud at work 27 10 (37.0) 0.90 (0.40-2.01) 
 
64 29 (45.3) 1.26 (0.74-2.15) 
 
381 151 (39.6) 
                   Contact with trash at work  24 5 (20.8) 0.59 (0.22-1.62) 
 
65 17 (26.2) 0.79 (0.44-1.44) 
 
379 117 (30.9) 
                  Contact with flood water at work 
during rainy season 26 9 (34.6) 0.84 (0.36-1.93) 
 
67 26 (38.8) 1.01 (0.59-1.71) 
 
380 147 (38.7) 
33 
 
Contact with sewer water at work 26 5 (19.2) 0.63 (0.23-1.72) 
 
65 19 (29.2) 1.10 (0.61-1.96) 
 
380 104 (27.4) 
 
          Use of boots or gloves during work** 30 6 (20.0) 0.97 (0.38-2.44) 
 
70 14 (20.0) 0.97 (0.51-1.82) 
 
384 79 (20.6) 
           Environmental Exposures 
            Residential sanitary conditions 
               Accumulation of trash <10m from home 43 36 (83.7) 1.18 (0.51-2.74) 
 
98 80 (81.6) 1.02 (0.58-1.79) 
 
446 363 (81.4) 
      Open sewer near home (<10m) 44 15 (34.1) 1.64 (0.85-3.18) 
 
98 26 (26.5) 1.15 (0.70-1.89) 
 
455 109 (24.0) 
       Street flood during rainy season 42 15 (35.7) 0.68 (0.35-1.31) 
 
101 44 (43.6) 0.95 (0.62-1.46) 
 
519 233 (44.9) 
       House flood during rainy season 27 5 (18.5) 0.96 (0.35-2.61) 
 
71 17 (23.9) 1.32 (0.72-2.42) 
 
364 70 (19.2) 
        Backyard flood during rainy season 6 2 (33.3) 0.90 (0.16-5.12) 
 
27 11 (40.7) 1.23 (0.52-2.92) 
 
109 39 (35.8) 
    Reservoirs 
                  Rats sighted near home 37 27 (73.0) 0.90 (0.42-1.91) 
 
98 88 (89.8) 2.93 (1.48-5.81) 
 
520 390 (75.0) 
        Number of rats observed near home 27 4.0 (2.0-6.0) 0.99 (0.90-1.09) 
 
87 4.0 (2.0-6.0) 1.02 (0.98-1.07) 
 
385 3.0 (2.0-5.0) 
        Dog as a domestic pet  44 18 (40.9) 0.94 (0.50-1.75) 
 
105 58 (55.2) 1.67 (1.10-2.55) 
 
525 223 (42.5) 
        Cat at residence 44 5 (11.4) 0.86 (0.33-2.26) 
 
105 18 (17.1) 1.39 (0.79-2.45) 
 
525 68 (13.0) 
        Chicken near residence 44 6 (13.6) 0.91 (0.37-2.21) 
 
105 13 (12.4) 0.81 (0.43-1.52) 
 
525 78 (14.9) 
No., number; %, percentage; IQR, interquartile range; OR, odds ratio; CI, confidence interval. Bold values indicate statistical 
significance (p-val <0.05). 
*Contact with contaminated source three weeks prior to hospitalization 










Table 4: Select characteristics to describe the clinical burden of leptospirosis among 1,316 suspected cases enrolled from the active  
hospital-based surveillance. 





 No. (%) or % of 










 No. (%) or % 











 No. (%) or % of 
group or Median 
(IQR) 
Clinical Presentation on admission 
           Days of symptoms before hospital 
admission (days) 111 5.0 (4.0-7.0) 0.13 181 5.0 (4.0-7.0) 0.06 999 6.0 (4.0-8.0) 
   Fever 110 103 (93.6) 0.21 181 174 (96.1) 0.99 1005 966 (96.1) 
   Dyspnea 95 63 (66.3) <0.0001 164 114 (69.5) <0.0001 833 132 (15.6) 
   Oliguria (<400ml/24h)§ 87 51 (58.6) <0.0001 160 70 (43.8) <0.01 852 263 (30.9) 
   Jaundice 111 88 (79.3) 0.29 183 147 (80.3) 0.33 1005 837 (83.3) 
   Hypotension (<90mm Hg) 106 17 (16.0) <0.01 178 31 (17.4) <0.0001 947 74 (7.8) 
Laboratory examinations* 
             Serum bilirubin (mg/dL) 
                  Total 70 8.1 (2.6-18.5) 0.76 103 10.0 (3.6-17.5) 0.96 577 10.1 (3.0-18.5) 
   Blood urea nitrogen (mg/dL) 
101 103.0 (61.0-165.0) 0.62 170 
114.0 (56.0-
170.0) 0.30 867 100.0 (57.0-164.0) 
   Serum creatinine (mg/dL) 101 3.1 (1.7-5.5) 0.08 171 3.1 (1.6-5.1) 0.05 864 2.6 (1.5-4.7) 
   Serum potassium 91 3.7 (3.5-4.3) 0.03 151 3.7 (3.2-4.3) 0.94 771 3.7 (3.3-4.2) 















    TGO  (U/L) 
107 126.0 (60.0-277.0) <0.001 173 
96.0 (60.0-
184.0) 0.02 968 86.0 (52.0-148.0) 
    TGP  (U/L) 
105 61.0 (44.0-117.0) 0.39 168 
68.0 (43.0-
108.0) 0.20 953 60.0 (39.0-97.0) 
    Hematocrit (%) 95 30.0 (26.0-34.0) <0.0001 162 33.5 (28.7-37.0) <0.001 836 35.0 (31.1-39.1) 
    Platelet Count (cells/mm^3) 93 
58000.0 (32000.0-
106000.0) <0.0001 159 
67000.0 
(36000.0-





    Thrombocytopenia** 93 39 (41.9) <0.0001 159 62 (39.0) <0.0001 816 185 (22.7) 
Complications during hospital stay 
             Oliguria (<400ml/24h) 99 83 (83.8) <0.0001 171 116 (67.8) <0.001 886 474 (53.5) 
Therapeutic Interventions 
             Mechanical Ventilation 72 64 (88.9) <0.0001 131 47 (35.9) <0.0001 490 0 (0.0) 
     Dialysis (Peritoneal or Hemodialysis) 107 59 (55.1) <0.0001 183 80 (43.7) <0.0001 995 184 (18.5) 
     ICU admission 108 93 (86.1) <0.0001 181 88 (48.6) <0.0001 995 156 (15.7) 
     Packed erythrocyte transfusion 107 60 (56.1) <0.0001 183 47 (25.7) <0.0001 993 90 (9.1) 
Hospital Outcome 
             Death  109 74 (67.9) <0.001 184 56 (30.4) <0.001 1001 63 (6.3) 
     Days of Hospitalization for survivors  33 19.0 (11.0-28.0) <0.0001 128 11.0 (7.0-16.0) <0.0001 936 7.0 (5.0-10.0) 
     Days of Hospitalization for patients 
who died  73 3.0 (1.0-5.0) 0.83 54 2.0 (1.0-4.0) 0.60 63 2.0 (1.0-6.0) 
Availability of Serum Samples 
              All Paired serum samples  113 57 (50.4) <0.0001 184 137 (74.5) <0.01 1019 844 (82.8) 
      Paired Serum Samples! 113 24 (21.2) <0.001 184 53 (28.8) 0.02 1019 388 (38.1) 
      Single serum sample 113 52 (46.0) <0.0001 184 41 (22.3) 0.04 1019 164 (16.1) 
      No serum sample 113 4 (3.5) 0.03 184 6 (3.3) 0.02 1019 11 (1.1) 
Confirmed Cases$ 113 79 (69.9) <0.01 184 134 (72.8) <0.01 1019 836 (82.0) 
      Serovar Copenhageni as the 
presumptive infecting agent^ 60 56 (93.3) 0.03 102 95 (93.1) 0.03 650 612 (94.2) 
Serological test (MAT) Result 
              First Acute sample titer  44 0.0 (0.0-150.0) <0.001 95 0.0 (0.0-400.0) <0.001 406 200.0 (0.0-1600.0) 
      Second Acute sample titer  
23 
1600.0 (0.0-
6400.0) 0.11 68 
3200.0 (800.0-
6400.0) 0.98 297 
3200.0 (800.0-
6400.0) 
      Convalescent sample titer 
19 
6400.0 (800.0-
6400.0) 0.36 64 
6400.0 (1200.0-
12800.0) 0.02 286 
3200.0 (400.0-
6400.0) 
No., number; %, percentage; IQR, interquartile range. Bold values indicate statistical significance (p-val <0.05). The Chi-square test 
or Fisher’s Exact test was used to evaluate significant differences for categorical data. The Wilcoxon-Rank Sum test was used to 
compare two groups for non-parametrically distributed continuous data.  
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#p-value shown is a pairwise comparison between LPHS and Non-LPHS, NHPL cases 
##p-value shown is a pairwise comparison between NHPL and Non-LPHS, NHPL cases 
§Oliguria within the first 24h upon hospital admission 
*Values obtained on hospital admission 
**Platelet count <50,000 cells/mm
3 
$The MAT, IgM ELISA, real time PCR, and Culture Isolation of Leptospires were used for laboratory confirmation 
^Proportions are shown for patients who had an MAT-confirmed diagnosis of leptospirosis and highest agglutination titers against 
Leptospirosis interrogans serovar Copenhageni 






















Census  Incidence RR 95% CI Age Group 
          All ages 82 2,675,656 0.31 64 1,248,897 0.51 18 1,426,759 0.13 4.06 4.10-4.11 
             0-14 0 552,800 0.00 0 301,847 0.00 0 272,707 0.00 1.00 NA 
             15-29 33 753,900 0.44 25 461,889 0.54 8 392,495 0.20 2.66 2.65-2.66 
             30-44 18 679,327 0.26 16 271,382 0.59 2 365,530 0.05 10.78 10.73-10.83 
             45-59 19 441,983 0.43 12 177,211 0.68 7 243,870 0.29 2.36 2.35-2.37 
             60+ 12 247,646 0.48 11 36,568 3.01 1 152,157 0.07 45.77 45.48-46.07 


















Census  Incidence RR 95% CI Age Group 
          All ages 917 2,675,656 3.43 781 1,248,897 6.25 136 1,426,759 0.95 6.56 6.62-6.63 
             0-14 40 552,800 0.72 34 301,847 1.13 6 272,707 0.22 5.12 5.11-5.13 
             15-29 316 753,900 4.19 290 461,889 6.28 26 392,495 0.66 9.48 9.47-9.49 
             30-44 295 679,327 4.34 253 271,382 9.32 42 365,530 1.15 8.11 8.11-8.12 
             45-59 206 441,983 4.66 164 177,211 9.25 42 243,870 1.72 5.37 5.37-5.38 
             60+ 60 247,646 2.42 40 36,568 10.94 20 152,157 1.31 8.32 8.31-8.34 
            
 
All Cases (LPHS and non-LPHS) 
 
 













Census  Incidence RR 95% CI Age Group 
          All ages 999 2,675,656 3.73 845 1,248,897 6.77 154 1,426,759 1.08 6.27 6.33-6.34 
             0-14 40 552,800 0.72 34 301,847 1.13 6 272,707 0.22 5.12 5.11-5.13 
             15-29 349 753,900 4.63 315 461,889 6.82 34 392,495 0.87 7.87 7.86-7.88 
             30-44 313 679,327 4.61 269 271,382 9.91 44 365,530 1.20 8.23 8.23-8.24 
             45-59 225 441,983 5.09 176 177,211 9.93 49 243,870 2.01 4.94 4.94-4.95 
             60+ 72 247,646 2.91 51 36,568 13.95 21 152,157 1.38 10.11 10.09-10.12 
No., number; RR, relative risk; CI, confidence interval. Mean annual incidence is shown as per 100,000 
persons. Indirect age standardization performed using the 2010 Population Census of Salvador-Bahia, 
Brazil from the Instituto Brasileiro de Geografia e Estatística (IBGE). Relative risk and 95% CI values 
calculated, using Poisson regression modeling for rates of leptospirosis in males compared to females. 
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S2. Case fatality rate and associated 95% confidence intervals for all suspected cases of LPHS, NHPL, and NPL patients. 
 
 














NPL % CFR 95% CI 
0-14 3 5 60.00 22.91-88.40 0 7 0.00 0.00-40.44 1 46 2.17 0.00-12.38 
15-29 20 42 47.62 33.36-62.28 6 53 11.32 4.93-22.94 11 366 3.01 1.62-5.36 
30-44 21 27 77.78 58.90-89.74 24 60 40.00 28.56-52.65 15 324 4.63 2.77-7.56 
45-59 21 25 84.00 64.73-94.21 21 48 43.75 30.69-57.73 27 222 12.16 8.45-17.16 
60+ 9 14 64.29 38.60-83.82 5 16 31.25 13.91-55.85 9 61 14.75 7.73-25.95 
Total 74 113 65.49 56.33-73.63 56 184 30.43 24.23-37.44 63 1019 6.18 4.85-7.84 






SF1: Generalized additive models (GAM) of the association between the acquisition of 
leptospirosis A. LPHS, B. NHPL, C. NPL and the continuous variable of age. D. Death and the 
continuous variable of age. Spline (Age) is the univariate smoothing term used to fit the non-
linear relationship between age and outcome (type of leptospirosis, death). Shaded areas 




































S3. A summary of the serological status of all suspected cases of leptospirosis enrolled in the 
hospital-based active surveillance. Laboratory confirmation of patients with leptospirosis shown 
is defined as a positive MAT, IgM ELISA, real-time PCR, or culture isolation of leptospires. 
Probable cases include individuals who have a borderline positive IgM ELISA without 
seroconversion or a reciprocal MAT titer of 200 or 400 without seroconversion. 
 
Disease Form                                
(No. Suspected Cases) 
Confirmed 




Unconfirmed (n=250)       
No. (%)* 
All (1316) 1049 (79.7) 17 (1.3) 250 (19.0) 
      LPHS (113) 79 (69.9) 5 (4.4) 29 (25.7) 
      NHPL (184) 134 (72.8) 3 (1.6) 47 (25.5) 
      NPL (1019) 836 (82.0) 9 (0.9) 174 (17.1) 
No., number; MAT, microagglutination test; ELISA, enzyme-linked immunosorbent assay; PCR, 
polymerase chain reaction.  Among the unconfirmed, 21 out of 1,316 cases did not have a 
laboratory test performed.  









S4.  Progression of pulmonary hemorrhage among 113 patients with leptospirosis associated pulmonary hemorrhage syndrome on day 









No. Responses No. (%) or 
group %   
No. Responses No. (%) or 
group % 
   Pulmonary hemorrhage in first 24h 91 42 (46.2) 
 
-- -- 
   Any hemoptysis 95 39 (41.1) 
 
108 107 (99.1) 
   Type of hemoptysis 39 
  
107 
             <300 mL blood 23 59.0% 
 
3 2.8% 
             >300 mL blood 12 30.8% 
 
22 20.6% 
             Blood in tracheal tube 1 2.6% 
 
60 56.1% 
             Massive bleeding in endotracheal tube after extubation 3 7.7%   22 20.6% 
No., number; LPHS, leptospirosis pulmonary hemorrhage syndrome.  
*Presentation on admission or within the first 24hrs post-admission. 







S5. A comparison of characteristics among laboratory confirmed versus laboratory unconfirmed patients.  
 




 No. (%) or % of 




 No. (%) or % of 




 No. (%) or % of group 





       Age (years)   1316 34.0 (24.0-47.0) 1049 33.0 (23.0-46.0) 267 38.0 (26.0-49.0) <0.01 
                05-14 58 4.4% 44 4.2% 14 5.2% 
                 15-29 461 35.0% 392 37.4% 69 25.8% 
                 30-44 411 31.2% 321 30.6% 90 33.7% 
                 45-59 295 22.4% 223 21.3% 72 27.0% 
                 60+ 91 6.9% 69 6.6% 22 8.2% 







     Female 203 15.4% 151 14.4% 52 19.5% 
      Male 1113 84.6% 898 85.6% 215 80.5% 





       Black 352 26.8% 306 29.2% 46 17.2% <0.0001 
     Other 964 73.3% 743 70.8% 221 82.8% 
 Clinical Presentation on 
admission 
          Days of symptoms before 
hospital admission (days) 1291 6.0 (4.0-8.0) 1036 6.0 (5.0-8.0) 255 5.0 (3.0-8.0) 0.001 
   Fever 1296 1243 (95.9) 1038 1003 (96.6) 258 240 (93.0) 0.01 
   Jaundice 1299 1072 (82.5) 1044 888 (85.1) 255 184 (72.2) <0.0001 
   Hypotension (<90mm Hg) 1231 122 (9.9) 988 83 (8.4) 243 39 (16.1) <0.001 
   Cough 553 190 (34.4) 443 159 (35.9) 110 31 (28.2) 0.13 
   Dyspnea 1092 309 (28.3) 891 239 (26.8) 201 70 (34.8) 0.02 
Laboratory examinations* 
       
43 
 
     Serum bilirubin (mg/dL) 
                 Total 750 10.0 (3.1-18.1) 614 11.1 (4.4-19.0) 136 3.7 (1.2-12.1) <0.0001 
          Direct 836 7.8 (2.1-14.2) 678 8.9 (3.2-15.0) 158 2.5 (0.6-10.2) <0.0001 
   Blood urea nitrogen (mg/dL) 1138 102.5 (57.0-165.0) 927 106.0 (62.0-164.0) 211 76.0 (35.0-172.0) <0.001 
   Serum creatinine (mg/dL) 1136 2.8 (1.5-4.8) 924 2.9 (1.6-5.0) 212 2.2 (1.2-4.4) 0.001 
   Serum potassium 1013 3.7 (3.3-4.2) 835 3.6 (3.2-4.1) 178 4.0 (3.5-4.6) <0.0001 
          <3.0 mmol/L 100 2.7 (2.6-2.8) 87 2.7 (2.6-2.8) 13 2.5 (2.2-2.7) 
            3.0-3.49 mmol/L  253 3.2 (3.1-3.3) 228 3.2 (3.1-3.3) 25 3.2 (3.1-3.3) 
            3.5-5.0 mmol/L  605 3.9 (3.7-4.3) 487 3.9 (3.6-4.3) 118 4.1 (3.8-4.5) 
            >5.0 mmol/L 55 5.5 (5.2-5.9) 33 5.4 (5.1-5.9) 22 5.6 (5.2-5.9) 
     TGO  (U/L) 1248 90.0 (52.0-160.0) 1003 89.0 (54.0-151.0) 245 90.0 (42.0-190.0) 0.80 
    TGP  (U/L) 1226 60.5 (40.0-100.0) 981 60.0 (41.0-93.0) 245 68.0 (38.0-144.0) 0.04 
    Hematocrit (%) 1093 34.5 (30.3-38.8) 893 34.1 (30.3-38.0) 200 36.0 (30.6-42.0) <0.001 







    Thrombocytopenia** 1068 286 (26.8) 872 240 (27.5) 196 46 (23.5) 0.25 
















Complications during hospital 
stay 
            Oliguria (<400ml/24h) 1156 673 (58.2) 938 550 (58.6) 218 123 (56.4) 0.55 
     Mechanical Ventilation 693 111 (16) 548 73 (13.3) 145 38 (26.2) <0.001 
     LPHS 1316 113 (8.6) 1049 79 (7.5) 267 34 (12.7) 0.01 
     NHPL without mechanical 
ventilation 1316 186 (14.1) 1049 140 (13.4) 267 46 (17.2) 0.10 
    NHPL without LPHS 1316 184 (14) 1049 134 (12.8) 267 50 (18.7) 0.01 
    NPL 1316 1019 (77.4) 1049 836 (79.7) 267 183 (68.5) <0.0001 
Hospital Outcome 
            Death  1294 193 (14.9) 1036 104 (10.0) 258 89 (34.5) <0.0001 




     Days of Hospitalization for 
patients who died  190 2.0 (1.0-5.0) 101 3.0 (1.0-7.0) 89 1.0 (1.0-3.0) <0.01 
Availability of Serum Samples 
             Paired serum samples  1316 1038 (78.9) 1049 894 (85.2) 267 144 (53.9) <0.0001 
      Single serum sample 1316 257 (19.5) 1049 155 (14.8) 267 102 (38.2) <0.0001 
      No serum sample* 1316 21 (1.6) 1049 0 (0.0) 267 21 (7.9) <0.0001 
No., number; %, percentage; IQR, interquartile range; OR, odds ratio; CI, confidence interval. Bold values indicate statistical 
significance (p-val <0.05). The Chi-square test or Fisher’s Exact test was used to evaluate significant differences for categorical data. 
The Wilcoxon-Rank Sum test was used to compare two groups for non-parametrically distributed continuous data.  
#p-value shown is a pairwise comparison between individuals with laboratory confirmation and no laboratory confirmation for 
leptospirosis. 
*Values obtained on hospital admission 
**Platelet count <50,000 cells/mm
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